
Penumbra (PEN) Stock Forecast & Price Target
Penumbra (PEN) Analyst Ratings
Bulls say
Penumbra is a leading thrombectomy company with innovative technology and a strong portfolio of products, including the recently launched THUNDERBOLT, which addresses a critical need in stroke care. The company's ability to continuously innovate and its low sales force turnover supports our expectation of double-digit revenue growth in the foreseeable future. We have a price target of $374 based on a DCF and EV-to-sales multiple, reflecting potential acquisition by Boston Scientific which we see as the most likely acquirer. The acquisition price reflects market expectations for the deal to go through, which is consistent with our expectation.
Bears say
Penumbra is facing strong competition in the neurovascular market from larger companies, and their premium pricing strategy may be difficult to sustain without near-perfect success rates. With the potential for a higher bid already priced in, any failure to change the treatment paradigm could negatively impact their growth potential.
This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares